UK to identify barriers to commercialisation of regenerative medicines
This article was originally published in RAJ Devices
Executive Summary
The UK government has launched a stock-taking exercise to gauge the latest developments in the field of regenerative medicine1. The aim is to identify barriers to commercialisation and clinical application and assess what actions the National Health Service should take to prepare for new treatments.
You may also be interested in...
Labeling Changes In Store For Hydroxychloroquine In EU After COVID-19 Experience
The risk of psychiatric disorders with chloroquine and hydroxychloroquine-containing medicines received renewed attention in the EU after they were being used as potential treatments for COVID-19.
UK Warns Against Printing Out EHRs For Clinical Trial Monitors
New UK guidance explains how clinical trial sponsors and investigator sites can ensure that trial monitors securely process data in electronic health record systems that do not have a restricted access functionality.
Swissmedic Clears Up Confusion Over Validity Of GMP Certificates
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Need a specific report? 1000+ reports available
Buy Reports